外显子组测序作为严重中枢神经系统结构异常胎儿的一线检测
该回顾性研究纳入114例因产前超声发现严重中枢神经系统异常而终止妊娠的胎儿,先行染色体微阵列分析(CMA),CMA阴性者行外显子组测序(ES)。CMA检出致病或可能致病拷贝数变异11/114(10%),86例CMA阴性者中ES检出38/86(44%)致病或可能致病变异;ES对10例CMA阳性病例再分析也检出全部致病或可能致病拷贝数变异。作者认为ES可作为严重胎儿中枢神经系统异常产前诊断的一线检测考虑。
要点
- 严重胎儿中枢神经系统异常中CMA检出致病或可能致病拷贝数变异11/114(10%)。
- CMA阴性者ES检出致病或可能致病变异38/86(44%)。
- ES可同时检出致病或可能致病变异和拷贝数变异。
核心结论
- ES在严重中枢神经系统结构异常胎儿中提供高诊断率(>50%),部分可能源于高度选择的病例系列,包括专科转诊中心终止妊娠后病例。
- 数据提示ES可考虑作为严重胎儿中枢神经系统异常产前诊断的一线检测,可检出致病或可能致病变异及拷贝数变异。
- 鉴于持续妊娠的时间限制及未来妊娠复发风险,这一点尤为重要。
研究设计与样本
- 回顾性研究,纳入114例因产前超声发现严重中枢神经系统异常而终止妊娠后转诊进行遗传评估的病例。
- 所有胎儿先行CMA分析,CMA阴性病例均接受ES检测。
- CMA阳性病例使用ES再分析以评估其检测拷贝数变异的能力。
主要发现
- CMA在11/114(10%)例中检出致病或可能致病拷贝数变异。
- 86例CMA阴性病例经ES分析,在38/86(44%)例中检出致病或可能致病变异。
- 复发 cases(即既往有受累妊娠的病例)中致病或可能致病变异发生率与非复发 cases 相比无显著增高(12/19(63%)vs 26/67(39%);P = 0.06)。
- 38例经ES诊断的病例中,20例(53%)为遗传性且携带显著复发风险。
- 对10例CMA阳性病例的ES再分析显示,用于序列变异分析的生物信息学流程也检出了全部致病或可能致病拷贝数变异,以及三个既往已知的非致病性拷贝数变异。
临床怎么用
- 作者认为,ES可考虑作为严重胎儿中枢神经系统异常产前诊断的一线检测。
局限性
- 本研究为回顾性研究。
- 高诊断率可能部分源于高度选择的病例系列,包括专科转诊中心终止妊娠后病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prenatally detected central nervous system (CNS) anomalies present a diagnostic challenge. In this study, we compared the diagnostic yield of exome sequencing (ES) and chromosomal microarray analysis (CMA) in fetuses with a major CNS anomaly. METHODS: This was a retrospective study of 114 cases referred for genetic evaluation following termination of pregnancy (TOP) due to a major CNS anomaly detected on prenatal ultrasound. All fetuses were first analyzed by CMA. All CMA-negative cases were offered ES. CMA-positive cases were reanalyzed using ES to assess its ability to detect copy-number variants (CNVs). RESULTS: CMA identified a pathogenic or likely pathogenic (P/LP) CNV in 11/114 (10%) cases. Eighty-six CMA-negative cases were analyzed using ES, which detected P/LP sequence variants in 38/86 (44%). Among recurrent cases (i.e. cases with a previously affected pregnancy), the incidence of P/LP sequence variants was non-significantly higher compared with non-recurrent ones (12/19 (63%) vs 26/67 (39%); P = 0.06). Among the 38 cases with an ES diagnosis, 20 (53%) were inherited and carried a significant risk of recurrence. Reanalysis of 10 CMA-positive cases by ES demonstrated that the bioinformatics pipeline used for sequence variant analysis also detected all P/LP CNVs, as well as three previously known non-causative CNVs. CONCLUSIONS: In our study, ES provided a high diagnostic yield (> 50%) in fetuses with severe CNS structural anomalies, which may have been partly due to the highly selected case series that included post-TOP cases from a specialist referral center. These data suggest that ES may be considered as a first-tier test for the prenatal diagnosis of major fetal CNS anomalies, detecting both P/LP sequence variants and CNVs. This is of particular importance given the time constraints of an ongoing pregnancy and the risk of recurrence in future pregnancies. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Yaron Y, Ofen Glassner V, Mory A, et al. Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies. Ultrasound Obstet Gynecol. 2022. PMID: 35229910. doi:10.1002/uog.24885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。